Published in Pharma Investments, Ventures and Law Weekly, November 6th, 2005
For the quarter ended July 31, 2005, Alexion reported revenues of $203,000 compared to $4.15 million for the same period last year. During the fourth quarter last year, the company had recognized a $4 million milestone payment from Procter & Gamble Pharmaceuticals (P&G) related to the APEX-AMI trial.
Total operating expenses for the quarter were $33.83 million compared to $23.37 million in the same quarter last year. The company's research and development expenses for the 3-month period ended July 31, 2005, were $27.62 million...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.